Expression of α-gal epitopes on ovarian carcinoma membranes to be used as a novel autologous tumor vaccine

Gynecologic Oncology

Volumn 90, Issue 1, 2003, Pages 100-108

  Galili, Uri ^a   Chen, Zhao chun ^a   DeGeest, Koen ^a,b  

^a RUSH UNIVERSITY   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1,3 GALACTOSYLTRANSFERASE; AUTOLOGOUS TUMOR VACCINE; CARBOHYDRATE; EPITOPE; GALACTOSE; GALACTOSYLTRANSFERASE; GLYCOPROTEIN; IMMUNOGLOBULIN G ANTIBODY; RECOMBINANT ENZYME; SIALIDASE; TUMOR VACCINE; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE GALACTOSE; ALPHA GALACTOSYL EPITOPE; ALPHA-GALACTOSYL EPITOPE; CANCER VACCINE; IMMUNOGLOBULIN G; MEMBRANE PROTEIN; N ACETYLLACTOSAMINIDE ALPHA 1,3 GALACTOSYLTRANSFERASE; N-ACETYLLACTOSAMINIDE ALPHA-1,3-GALACTOSYLTRANSFERASE; TRISACCHARIDE;

ANIMAL CELL; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN PURIFICATION; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOGENICITY; NONHUMAN; OPSONIZATION; OVARY CANCER; PRIORITY JOURNAL; RABBIT; TISSUE HOMOGENATE; BIOSYNTHESIS; BLOOD; CARBOHYDRATE ANALYSIS; CELL MEMBRANE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; OVARY TUMOR;

ANTIGEN-PRESENTING CELLS; CANCER VACCINES; CARBOHYDRATE SEQUENCE; CELL MEMBRANE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; GALACTOSYLTRANSFERASES; HUMANS; IMMUNOGLOBULIN G; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; NEURAMINIDASE; OVARIAN NEOPLASMS; TRISACCHARIDES; URIDINE DIPHOSPHATE GALACTOSE;

EID: 0038500735     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00148-3     Document Type: Article

References (43)

1. Livingston P. Active specific immunotherapy in the treatment of patients with cancer. Immunol Allerg Clin North Am. 11:1991;401-410.
2. Pardoll D.M. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol. 2:2002;227-238.
3. Hainaut P., Weynants P., Coulie P.G., Boon T. Antitumor T-lymphocyte response. Med Clin North Am. 10:1990;639-653.
4. Old L.J. Immunotherapy for cancer. Sci Am. Sept:1996;136-143.
5. Pardoll D.M. Cancer vaccines. Immunol Today. 14:1993;310-316.
6. Guinan E.C., Gribben J.G., Boussiotis V.A., Freeman G.J., Nadler L.M. Pivotal role of the B7 CD28 pathway in transplantation, tolerance and tumor immunity . Blood. 84:1994;3261-3282.
7. Chen L., Ashe S., Brady W.A., Hellström I., Hellström K.E., Ledbetter J.A., et al. Costimulation of anti-tumor immunity by the B7 counterreceptor for the T-lymphocyte molecule CD-28 and CTLA-4. Cell. 71:1992;1093-1102.
8. Townsend S.E., Allison J.P. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science. 259:1993;368-370.
9. Lanzavecchia A. Mechanism of antigen uptake for presentation. Curr Opin Immunol. 8:1996;348-354.
10. Grabbe S., Beisserts S., Schwartz T., Granstein R.D. Dendritic cells as initiators of tumor immune response a possible strategy for tumor immunotherapy . Immunol Today. 16:1995;117-121.
11. Schwartz R.H. Costimulation of T lymphocytes the role of CD28, CTLA-4 and B7/BB1 in interleukin-2 production and immunotherapy . Cell. 71:1992;1065-1068.
12. Maass G., Schmidt W., Berger M., Schilcher F., Koszik F., Schneeberger A., et al. Primary of tumor-specific T cells in the draining lymph nodes after immunization with interleukin-2 secreting tumor cells three consecutive stages may be required for successful tumor vaccination . Proc Natl Acad Sci USA. 92:1995;5540-5544.
13. Zinkernagel R.M., Ehl E., Aichele P., Kündig T., Hengartner H. Antigen localization regulates immune responses in a dose and time dependent fashion a geographical view of immune reactivity . Immunol Rev. 156:1997;199-209.
14. Nossal D.J.V. Tolerance and ways to break it. Ann NY Acad Sci. 690:1993;34-41.
15. Unkeless J.C. Functional heterogeneity of human Fc receptors for immunoglobulin G. J Clin Invest. 83:1989;355-561.
16. Fanger N.A., Wardwell K., Shen L., Tedder T.F., Guyre P.M. Type I (CD64) and type II (CD32) Fc receptor-mediated phagocytosis by human blood dendritic cells. J Immunol. 157:1996;541-548.
17. Schmitt D.A., Hanan D., Bieber T., Dezutter-Dambuyant C., Schmitt D., Fabre M., et al. Human epidermal Langerhans cells express only trhe 40-kilodalton Fcγ receptor (FcRII). J Immunol. 144:1990;4284-4290.
18. Clynes R., Takechi Y., Moroi Y., Houghton A., Ravetch J.V. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci USA. 95:1998;652-656.
19. LaTemple D.C., Henion T.R., Anaraki F., Galili U. Synthesis of α-galactosyl epitopes by recombinant α1,3galactosyl transferase for opsonization of human tumor cell vaccines by anti-galactose. Cancer Res. 56:1996;3069-3074.
20. Galili U., LaTemple D.C. The natural anti-Gal antibody as a universal augmenter of autologous vaccine immunogenicity. Immunol Today. 18:1997;281-285.
21. Galili U., Rachmilewitz E.A., Peleg A., Flechner I. A unique natural human IgG antibody with anti-α-galactosyl specificity. J Exp Med. 160:1984;1519-1531.
22. Galili U., Macher B.A., Buehler J., Shohet S.B. Human natural anti-α-galactosyl IgG. II. The specific recognition of α(1-3) -linked galactose residues. J Exp Med. 162:1985;573-582.
23. Galili U., Buehler J., Shohet S.B., Macher B.A. The human natural anti-Gal IgG. III. The subtlety of immune tolerance in man as demonstrated by crossreactivity between natural anti-Gal and anti-B antibodies. J Exp Med. 165:1987;693-704.
24. Galili U. Evolution and pathophysiology of the human natural anti-Gal antibody. Springer Semin Immunopathol. 15:1993;155-171.
25. Galili U., Mandrell R.E., Hamadeh R.M., Shohet S.B., Griffis J.M. Interaction between human natural anti-α-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun. 56:1988;1730-1737.
26. Galili U., Clark M.R., Shohet S.B., Buehler J., Macher B.A. Evolutionary relationship between the anti-Gal antibody and the Galα1-3Gal epitope in primates. Proc Natl Acad Sci USA. 84:1987;1369-1373.
27. Galili U., Shohet S.B., Kobrin E., Stults C.L.M., Macher B.A. Man, apes, and Old World monkeys differ from other mammals in the expression of α-galactosyl epitopes on nucleated cells. J Biol Chem. 263:1988;17755-17767.
28. Galili U. Interaction of the natural anti-Gal antibody with α-galactosyl epitopes a major obstacle for xenotranplantation in humans . Immunol Today. 14:1993;480-482.
29. Collins B.H., Cotterell A.H., McCurry K.R., Alvarado C.G., Magee J.C., Parker W., et al. Cardiac xenografts between primate species provide evidence for the importance of α-galactosyl determinant in hyperacute rejection. J Immunol. 154:1995;5500-5510.
30. Galili U., Chen Z.C., Manches O., Plumas J., Preisler H. Preparation of autologous leukemia and lymphoma vaccines expressing α-gal epitopes. J Hematother Stem Cell Res. 10:2001;501-511.
31. LaTemple D.C., Abrams J.T., Zhang S.U., Galili U. Increased immunogenicity of tumor vaccines complexed with anti-Gal studies in knock out mice for α1,3galactosyltranferase . Cancer Res. 59:1999;3417-3423.
32. Henion T.R., Macher B.A., Anaraki F., Galili U. Defining the minimal size of catalytically active primate α1,3galactosyltransferase structure function studies on the recombinant truncated enzyme . Glycobiology. 4:1994;192-210.
33. Chen Z.C., Tanemura M., Galili U. Synthesis of α-gal epitopes on human tumor cells by recombinant α1,3galactosyltransferase produced in Pichia pastoris. Glycobiology. 11:2001;577-586.
34. Galili U., LaTemple D.C., Radic M.Z. A sensitive assay for measuring α-Gal epitope expression on cells by a monoclonal anti-Gal antibody. Transplantation. 65:1998;1129-1132.
35. 4 isolated from Bandeiraea simplicifolia. Arch Biochem Biophys. 198:1979;1-11.
36. Galili U., Tibell A., Samuelsson B., Rydberg L., Groth C.G. Increased anti-Gal activity in diabetic patients transplanted with fetal porcine islet cell clusters. Transplantation. 59:1995;1549-1556.
37. Stone K.R., Ayala G., Goldstein J., Hurst R., Walgenbach A., Galili U. Porcine cartilage transplants in cynomolgus monkey III. Transplantation of α-galactosidase treated porcine cartilage . Transplantation. 65:1998;1577-1583.
38. Tanemura M., Maruyama S., Galili U. Differential expression of α-gAL epitopes (Galα1-3Galβ1-4GlcNAc-R) on pig and mouse organs. Transplantation. 69:2000;187-190.
39. Berd D., Maguire H.C. Jr, Schuchter L.M., Hamilton R., Hauch W.W., Soto T., et al. Autologous, hapten-modified melanoma vaccine as post-surgical adjuvant treatment after resection of nodal metastases. J Clin Oncol. 15:1997;2359-2370.
40. Berd D., Sato T., Cohn H., Maguire H.C. Jr, Mastrangelo M.J. Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine regression of pulmonary metastases . Int J Cancer. 94:2001;531-539.
41. Bekeshi J.G., Holland J.F., Roboz J.P. Specific immunotherapy with neuraminidase-modified leukemic cells experimental and clinical trials . Med Clin North Am. 61:1977;1083-1100.
42. Bekesi J.G., Roboz J.P., Holland J.F. Therapeutic effectiveness of neuraminidase treated tumor cells as an immunogen in man and experimental animals with leukemia. Ann NY Acad Sci. 277:1976;313-319.
43. Groth C.G., Korsgren O., Tibel A., Tollerman J., Muller E., Bolinder J., et al. Transplantation of fetal porcine pancreas to diabetic patients biochemical and histological evidence for graft survival . Lancet. 344:1994;1402-1404.